Inclusion Criteria:

          -  Diagnosis of recurrent or metastatic SCCHN or any site except lip, thyroid, salivary
             gland, or nasopharynx.

          -  No known FDA-approved therapy available that's expected to prolong survival by greater
             than 3 months.

          -  Tumors with at least one of the following known mutations in the PI-3K signaling
             pathway, via assays performed in a CLIA-approved setting (Foundation Medicine
             FoundationOne test will be used. This assay uses a cut-off of 5% allele fraction for
             mutations. Allele fraction will be requested on each sample):

               1. PIK3CA,

               2. PIK3CG,

               3. PIK3R1, PIK3R5 and PIK3AP1 (regulatory subunits),

               4. AKT and mTOR, or

               5. PTEN Note: PIK3CA amplification is not eligible.

          -  Prior receipt of platinum-containing chemotherapy for recurrent/metastatic disease or
             a history of progression of disease within 6 months of receiving platinum as part of
             concurrent chemoradiation.

          -  Disease must not be amenable to potentially curative treatment..

          -  Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy,
             or radiotherapy.

               -  Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for
                  nitrosourea)

               -  Biologic (anti-neoplastic agent): At least 14 days since completion of therapy
                  with a biologic agent.

               -  Radiation (XRT):1 week must have elapsed from prior palliative XRT to non-target
                  lesions.

          -  Adequate Bone Marrow Function Defined for all subjects (including status post SCT):

               -  Peripheral absolute neutrophil count (ANC) 1000/mm3; Note: must be >7 days from
                  use of hematopoietic growth factor or 21 days from pegfilgastrim

               -  Platelet count 75,000/ mm3 (transfusion independent for >7 days)

               -  Hemoglobin 8.0 g/dL (may receive transfusions)

          -  Adequate Renal Function Defined As:

               -  Serum creatinine ≤ 1.5 x institution's ULN (upper limit of normal), or

               -  Creatinine clearance 50 ml/min

          -  Adequate Liver and Pancreatic Function Defined As:

               -  Total bilirubin 1.5 x upper limit of normal, and

               -  ALT or AST 5 x upper limit of normal, and

               -  Albumin 2 g/dL

          -  Adequate Central Nervous System Function Defined As:

               -  Subjects with seizure disorder may be enrolled if on anticonvulsants and seizures
                  are well controlled.

        Exclusion Criteria:

          -  Brain metastases or spinal cord compression, unless treatment was completed at least 4
             weeks before study entry, and stable without steroid treatment for at least 4 weeks.

          -  Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
             respiratory, cardiac [including life threatening arrhythmias], hepatic, or renal
             disease).

          -  Unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy except alopecia
             or long-term radiation toxicity (radiation related toxicity 3 months or greater after
             radiation exposure).

          -  Presence of cardiac impairment defined as:

               -  Prior history of cardiovascular disease including heart failure that meets New
                  York Hearth Association (NYHA) class III and IV definitions; OR

               -  History of myocardial infarction/active ischemic heart disease within one year of
                  study entry; OR

               -  Uncontrolled dysrhythmias; OR

               -  Poorly controlled angina.

          -  Participation in a trial of an investigational agent within the prior 30 days.

          -  Pregnant or breast-feeding females.

          -  History of other malignancies except curatively excised carcinoma in situ of the
             cervix, non-melanomatous skin carcinoma or superficial bladder cancer or other solid
             tumors curatively treated with no evidence of disease for 3 years. Other cases will be
             reviewed and possibly allowed if discussed with and approved by the Principal
             Investigator.

          -  Patients receiving therapeutic doses of warfarin.

          -  Blood pressure greater than 170/90 or two standard deviations from normal based on age
             and weight nomogram on three separate measurements.